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Background: It is unclear how mutations in the 
coiled-coil tail of β-cardiac myosin cause heart 
disease. 
Results: Effects of disease-causing mutations in 
the myosin tail were studied in vivo and in vitro.  
Conclusion: Mutations that reduce helical content 
in vitro reduce sarcomere incorporation of myosin 
in vivo.  
Significance: A change in myosin tail structure 
can lead to heart disease.    
 
SUMMARY 
It is unclear why mutations in the filament 
forming tail of myosin heavy chain (MHC) 
cause hypertrophic (HCM) or dilated (DCM) 
cardiomyopathy as these mutations should not 
directly affect contraction. To investigate this, 
we first investigated the impact of five HCM-
causing (N1327K, E1356K, R1382W, E1555K 
and R1768K) and one DCM-causing (R1500W) 
tail mutations on their ability to incorporate 
into muscle sarcomeres in vivo. We used 
adenoviral delivery to express full-length wild 
type or mutant eGFP-MHC in isolated adult 
cardiomyocytes. Three mutations (N1327K, 
E1356K and E1555K) reduced eGFP-MHC 
incorporation into muscle sarcomeres while the 
remainder had no effect. No mutations 
significantly affected contraction. Fluorescence 
recovery after photobleaching (FRAP) showed 
that fluorescence recovery for the mutation that 
incorporated least well (N1327K), was 
significantly faster than that of WT with half 
times of 25.1 ± 1.8 and 32.2 ± 2.5 minutes (mean 
± S.E.M.) respectively. Next, we determined the 
effects of each mutation on the helical 
properties of wild type and 7 mutant peptides 
(7, 11 or 15 heptads long) from the myosin tail 
by circular dichroism. R1382W and E1768K 
slightly increased the α-helical nature of 
peptides. The remaining mutations reduced α-
helical content, with N1327K showing the 
greatest reduction. Only peptides containing 
residues 1301-1329 were highly α-helical 
suggesting that this region helps in initiation of 
coiled coil. These results suggest that small 
effects of mutations on helicity translate into a 
reduced ability to incorporate into sarcomeres, 
which may elicit compensatory hypertrophy.  
β-cardiac myosin is a conventional class 2 
myosin expressed in the heart and in slow muscle. 
It contains two heavy and four light chains. The 
heavy chains dimerise by forming a coiled-coil tail 
in the C-terminal region of the molecule and 
separate to form two globular heads at their N-
terminal region. The globular head contains the 
motor domain, which binds actin and nucleotide 
and is responsible for generating contraction. The 
coiled-coil tail contains two α-helices that interact 
with each other to bury hydrophobic residues, 
forming a hydrophobic seam (1).  Each contains a 
distinctive heptad repeat sequence in the form of 
(abcdefg)n where a and d are commonly 
hydrophobic. Because the heptad repeat is slightly 
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shorter than two turns of an α-helix, the two 
helices twist around each other to form a coiled 
coil with a left-handed superhelix (2). The tail also 
contains four “skip” residues, nominally at 
positions T1188, E1385, E1582 and G1807, which 
interrupt the heptad motif and correlate to bends in 
the myosin tail in the isolated molecules (3).  The 
distal region of the coiled-coil tail assembles into 
thick filaments as a result of patterns of alternating 
charge along the length of the coiled coil (4), and a 
short assembly competence domain near the C-
terminus (5).   
Mutations in the gene for the heavy chain of β-
cardiac myosin (MYH7) (6) cause the disease 
hypertrophic cardiomyopathy (HCM), a global 
disease that causes heart failure, first described 
over 50 years ago (7). HCM is the most common 
cause of sudden death in people under thirty years 
of age (8) and affects at least 1 in 500 people. 
Mutations in MYH7 cause approximately 40% of 
cases of inherited HCM (9,10). The disease is 
characterised by thickening of the left ventricular 
wall and myocardial disarray (11). More generally, 
mutations in genes that encode sarcomeric proteins 
are responsible for HCM (12) with over 630 
mutations in 10 sarcomeric genes described as 
causing this disease.  Mutations in MYH7 also 
cause dilated cardiomyopathy (DCM), a rarer 
heart disease that only affects about 1 in 2500 
people (13), and characterised by a thinning of the 
ventricular walls (ventricular dilatation). 
Currently, over 200 HCM and 24 DCM mutations 
have been described for MYH7 (14), many of 
which result in a highly malignant form of the 
disease. However, tail mutations are rare and only 
limited descriptions of their severity and 
phenotype are available (Table S1). 
While a clear link between HCM causing 
mutations in the motor domain and HCM can be 
attributed to direct effects on force output (11), it 
is unclear why mutations in the distal tail result in 
HCM. As the main role of the tail is to form 
filaments, it is unlikely that mutations in the tail 
directly affect force output. However, effects on 
coiled-coil structure and/or packing of the coiled 
coil into the thick filament, might affect myosin 
incorporation into thick filaments in sarcomeres, 
and thus indirectly affect force output over the 
longer term.  
To test this idea, we investigated 5 different 
mutations that result in HCM (15-21) and one 
(R1500W) that causes dilated cardiomyopathy 
(DCM) (17). Only two of these mutations have 
been investigated previously (E1356K and 
R1500W (22,23)). In those reports, expressed and 
purified LMM peptides containing the mutation 
had decreased thermal stability, but the secondary 
structure was not affected. This suggested to us 
that any effects on secondary structure could be 
localised and not observable in the full-length 
LMM. Thus, in this study, we have used shorter 
peptides to investigate the effects of the mutations. 
Neither of these previous reports investigated the 
effects of these mutations in vivo. 
Here, we have investigated the effects of each 
of these mutations on the incorporation of full-
length β-cardiac myosin heavy chain, fused to 
eGFP (eGFP-MHC), in vivo. We used an 
adenoviral expression system to express eGFP-
MHC in adult rat cardiomyocytes, and determined 
whether these mutations affect incorporation of the 
full-length heavy chain into the sarcomere or 
contraction.  To determine if the effects we 
observed were correlated to effects on peptide 
structure in vitro, we analysed the secondary 
structure and thermal stability of peptides of 
different length. We used peptides that were 7, 11 
or 15 heptads long from the myosin coiled-coil tail 
to determine if any or all of the 5 different 
mutations affect molecular structure, and to 
determine if the effects observed depended on 
peptide length. 
 
EXPERIMENTAL PROCEDURES 
Expression and characterisation of eGFP-
MHC in adult cardiomyocytes - The full-length 
cDNA for the heavy chain of MYH7 (24) was 
cloned into an adenoviral expression vector 
(pdc315, Adgene) with eGFP fused to the N-
terminus to generate eGFP-MHC. A second 
construct, without eGFP was also constructed. 
Purified virus (at MOIs between 50 and 100) was 
used to infect isolated adult rat cardiomyocytes. 
These were prepared from isolated rat hearts using 
a Langendorff retrograde perfusion technique with 
a collagenase containing solution (25). After 
incubation for 24 hours at 37°C, to allow the MHC 
to be expressed, cells were fixed using 4% 
formaldehyde in phosphate buffered saline prior to 
staining for other proteins of interest.  Cells were 
stained with antibodies against an M-line epitope 
of titin (Ti51; kind gift of Dieter Furst (26)), or for 
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myosin heavy chain (A4.1025 antibody(27)), and 
cells were imaged using a Deltavision 
deconvolution microscope. 
Levels of eGFP-MHC expression were 
compared to endogenous levels of MHC by SDS 
gel analysis using a protocol that separates MHC 
isoforms in a minigel system (28). Briefly, the 
separating gel contained 35% v/v glycerol, 9%w/v 
acrylamide-Bis (49:1), 230mM Tris HCl, 115 mM 
glycine, pH 8.8 and 0.4% w/v SDS; and the 
stacking gel contained 47% v/v glycerol, 6% w/v 
acrylamide-Bis (49:1), 110 mM Tris HCl, 6 mM 
EDTA, pH 6.8 and 0.4% w/v SDS). Gels were 
stained, or proteins were transferred to 
nitrocellulose paper to perform western blotting, 
using an antibody to MHC (A4.1025) or to eGFP 
(Abcam). These blots confirmed which band was 
endogenous and which the eGFP-tagged myosin in 
the stained gel (Fig. 1).  
As expression levels were ~10% or less after 
24 hours, we also attempted to culture MHC 
expressing cardiomyocytes for longer time 
periods. However, we found that long-term culture 
of cardiomyocytes resulted in a loss of 
contractility of the intact cells and in a loss of the 
characteristic rod-shape, as previously 
documented (29). We also suspect that the large 
excess of the overexpressed MHC compared to 
other myosin-binding proteins (light chains, titin, 
MyBP-C, actin etc) that are also needed to 
incorporate and regulate the MHC into muscle 
sarcomeres contributed to the loss of contractility 
as large amounts of unregulated soluble non-
incorporated MHC may be toxic to the cells. Thus 
24 hours of myosin overexpression is the best 
compromise between expression of high enough 
levels of eGFP-MHC to observe the impacts of the 
mutants within the sarcomere and expression of 
such high levels that cell viability is lost. 
Fluorescence Recovery after Photobleaching 
(FRAP) - For FRAP experiments, cells were plated 
onto laminin-coated glass bottomed dishes (35mm, 
Iwaki), infected with the adenovirus, cultured 
overnight and imaged the following day using an 
inverted Zeiss 510 confocal microscope. Dishes 
were placed onto the heated stage (set to 37˚C), 
10-15 cells were selected, their positions marked, 
and a Zeiss multi-time series macro was 
programmed to image each cell in turn, bleach a 
small rectangular area in each cell, approximately 
2 sarcomeres in width, using 20 cycles of 
maximum laser power (at a wavelength of 
488nm), and then image each cell every 5-10 
minutes after bleaching for the next 105-125 
minutes at 1% laser power until fluorescence 
recovery reached a plateau. To analyse the data, 
the average intensity of the bleached area was 
measured at each time point using ImageJ. 
Recordings from cells that contracted, or 
underwent large movements during the experiment 
were discarded. The average image intensity of the 
same sized area in an area adjacent to that 
bleached was also measured, to test that the 
intensity of non-bleached regions did not change. 
Data were normalised as described (30). 
Exponential fits to the data were generated using 
Prism (Graphpad).  
Cardiomyocyte contraction - Within 18-24 
hours of infection, live cells were placed in a bath, 
continuously perfused with physiological saline at 
room temperature, and stimulated by external 
platinum electrodes at a frequency of 1Hz to 
investigate their ability to contract. Contraction 
was recorded using video edge detection (31), and 
analysed for the times to peak shortening and half 
relaxation together with contractility, indexed as 
the amplitude of shortening as a % of resting cell 
length. 
Expression and characterisation of coiled-coil 
peptides - Standard PCR based cloning was used 
to generate expression vectors for GST fusion 
proteins, using the MYH7 cDNA as a template. 
All constructs were sequence verified after 
cloning.  The resulting expression vectors were 
used to express peptides in E. coli. During 
purification, the GST was removed using 
Precission protease. All peptides (Table S2) 
contained the N-terminal sequence GPLGS in 
addition to the peptide sequence. Each peptide 
expressed was designed to start and end on a 
residue in the d position of the heptad repeat. 
Peptides were 55, 83 or 111 residues long (7, 11 or 
15 heptads, respectively).  The 7-heptad peptides 
were designed such that in mutants, the mutated 
residue was in the central heptad with 3 heptads on 
either side. The concentrations of the purified 
proteins were determined by a micro BCA assay 
(Pierce) and/or by measuring their absorbance at 
280nm in a quartz cuvette on a Cary-50 
spectrophotometer and using the extinction 
coefficient calculated from the sequence (using 
ProtParam (ExPASy)). 7-heptad peptides were 
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additionally analysed by mass spectrometry, to 
confirm that their molecular mass was correct.  
Circular dichroism - Circular dichroism spectra 
were measured from 260 to 190 nm at 10˚C using 
a Jasco J715 spectropolarimeter.  
For the 7H peptides, protein concentrations 
varied from 0.25 mg/ml to 0.05 mg/ml, and their 
CD spectra were obtained at 10˚C at pH 8.0 in 150 
mM NaCl, 10 mM phosphate buffer. Thermal melt 
data were obtained either in the same buffer, or in 
50 mM NaCl, 10 mM phosphate buffer, at pH 7.0. 
An increase in pH slightly increased the Tm 
(melting temperature) for all the peptides equally. 
1 mM DTT was added to peptides containing a 
cysteine residue.  
The effect of the mutations on α-helical content 
was estimated by comparing the value of the 
ellipticity measurements (θ222) at a wavelength of 
222nm, expressed as mean residue ellipticity in 
degrees cm2 dmol-1 for the peptides at 10˚C for all 
the constructs. The θ222 values indicate the relative 
helical content of the peptides. We therefore used 
θ222 values to compare helical content between the 
constructs. Repeat measurements for the majority 
of the 7H constructs gave consistent results, giving 
confidence that the observed differences between 
peptides are likely to be significant, especially 
where differences are large. Where more than 2 
repeats were performed for the 7H constructs, 
error bars are shown in Figure 5. To compare 
helical contents between peptides, the 222nm 
value was divided by -36,000 (theoretical value for 
100% helical content) (32) 
For the 11H and 15H peptides, protein 
concentrations varied from 0.25 mg/ml to 0.1 
mg/ml and their CD spectra were obtained at 10˚C 
in 50 mM NaCl, 10 mM phosphate buffer, pH 7.4. 
Further data obtained in the same buffer at pH 7.0 
(not shown) showed very little change in the 
spectra at a temperature of 10˚C. Three repeat 
measurements were made for each of the 11 and 
15H peptides, and t-tests used to determine if 
differences in helical content (estimated from the 
222nm value as described above) were significant.  
The effect of temperature on the α-helical 
content was measured by taking measurements at 
222 nm from 5 to 60˚C, for every 1˚C temperature 
change. The conditions used were 50 mM NaCl, 
10 mM phosphate buffer, at pH 7.0. Temperature 
was changed at a rate of 2˚C/min. The temperature 
was returned to 10˚C and the resulting spectrum 
was close to that measured prior to heating (value 
at 222 nm, to within a few per cent). The θ222 
measurements were normalised, by setting the 
value at 5˚C to 0% unfolded, and the value at 65˚C 
to 100% unfolded. The resulting plots of the θ222 
values were fit using the Boltzman sigmoidal fit 
function in Graph Pad Prism 6 software (33), to 
generate values for Tm.  
 
RESULTS 
Expression of full-length MHC in 
cardiomyocytes - WT eGFP-MHC was expressed 
successfully in isolated adult cardiomyocytes, and 
the eGFP-tagged MHC (in which eGFP is fused to 
the MHC N-terminus (motor domain)) 
incorporated into the thick filaments in muscle 
sarcomeres. eGFP-MHC began to be expressed 
and to incorporate into sarcomeres 6-7 hours after 
viral infection (Fig. S1). After 24 hours, the 
pattern of fluorescence for eGFP-MHC was 
similar to the immunostaining pattern for total 
MHC, using an antibody against an epitope in the 
motor domain (Fig. 1A).  
Both the anti-MHC immunostaining and the 
eGFP fluorescence show two stripes, separated by 
an unstained gap, which corresponds to the bare 
zone in the centre of the thick filament. The 
unstained gap at the M-line was wider (~0.3µm) 
for eGFP-MHC than for endogenous myosin (Fig. 
1B), suggesting that there is some limit on 
incorporation of new myosin in the centre of the 
thick filament, as reported earlier (34). The gap in 
intensity at the I-band is similar for eGFP-MHC 
and the immunostained image for MHC (Fig. 1B). 
Overall, the newly synthesised eGFP-MHC has 
incorporated generally throughout the thick 
filaments, and not only at the very edges of the A-
bands or at the periphery of the myofibrils, similar 
to that reported for embryonic chicken MHC in 
embryonic cardiomyocytes (35), although the 
fluorescence intensity is higher at the ends of the 
A-band. This suggests that myosin may exchange 
more easily at the ends of the thick filaments, 
because of the reduced number of interactions that 
myosin there makes with other myosins, as the 
thick filament tapers at this point. It is also 
possible that diffusion is faster within the I-band 
(less congested) than with the A-band, so that 
exchanging molecules are more likely to encounter 
thick filament ends 
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Impact of tail mutations on MHC uptake into 
myofibrils - Using the adenoviral expression 
system, we expressed and characterised six 
different tail mutants (N1327K, E1356K, 
R1382W, R1500W, E1555K and E1768K) in adult 
cardiomyocytes.  These mutations are all found in 
the tail of MHC (Table S2, Fig. 5A). WT and 
mutant eGFP-MHC were all expressed at a level 
of 5-10% of the endogenous myosin, following 24 
hours infection with the adenovirus as shown by 
SDS-PAGE gel and western blotting (Fig. 1B), 
with the exception of R1500W, which was 
expressed at slightly lower levels (~2% of 
endogenous myosin).  
Deconvolution microscopy of fixed 
cardiomyocytes containing expressed mutant 
eGFP-MHC isoforms showed that in the case of 
several mutants, eGFP-MHC did not incorporate 
into muscle sarcomeres as well as WT eGFP-
MHC in substantial numbers of cells (Fig. 2). 
Instead, eGFP-MHC incorporation was limited to 
regions at the edges at the A-bands, where it is 
mainly incorporated into the ends of the thick 
filament, and there were increased numbers of 
filamentous aggregates outside the myofibrils (Fig. 
2B). These filamentous aggregates are likely to 
contain eGFP-MHC that is unable to incorporate 
or exchange into the sarcomeric thick filaments. 
We repeated these experiments several times, and 
consistently observed this effect.  
Quantifying the proportions of cells with 
normal, or limited incorporation showed that the 
mutation N1327K resulted in the highest increase 
in the proportion of cells with limited 
incorporation of eGFP-MHC and this increase was 
significant (Fig. 2B). Two further mutations, 
E1356K and E1555K, also showed a trend towards 
an increase in numbers of cells with limited eGFP 
MHC incorporation. In the remaining three 
mutations, R1500W, R138W and E1768K, eGFP 
MHC incorporation was similar to wild type. The 
differences in incorporation are unlikely to be due 
to different levels of viral infection, as similar 
MOIs were used in all the experiments, and the 
expression levels of the eGFP MHC are low and 
uncorrelated with these differences (Fig. 1B). 
Exchange rate of MHC into myofibrils using 
FRAP - The expression of full length eGFP-MHC 
in living adult cardiomyocytes gave us the 
opportunity, for the first time, to investigate how 
quickly eGFP-MHC exchanges into thick 
filaments using FRAP for WT and mutant 
isoforms. For WT eGFP-MHC, the fluorescence 
recovery was slow, with a half time for recovery 
of 32.2 ± 2.5 minutes (mean ± S.E.M, n= 14) (Fig. 
3B). Recovery appeared to occur first in regions 
close to the Z-discs (arrowed, Fig 3A), before 
spreading through the rest of the A-band. While 
the rate of recovery was slow, these experiments 
showed that the myosin molecules are exchanging 
into and out of the thick filament more 
dynamically than we might have predicted.   
We extended these FRAP experiments to two 
different mutants, one that had the most effect on 
sarcomeric incorporation (N1327K) and one that 
had the least (R1382W). We found that the half 
time for fluorescence recovery was significantly 
faster (p<0.05) for N1327K (t½ of 25.1 ± 1.8 
minutes (n=18)), but not for R1382W (t½ of 31.0 ± 
1.6 minutes (n=18)) compared to WT eGFP-MHC 
(Fig. 3B). These results suggest that the poorer 
incorporation of the N1327K mutation is linked to 
an increase in the rate of exchange of the MHC 
into thick filaments. The rate of myosin exchange 
into the thick filaments is partly determined by the 
rate at which the incoming myosin incorporates, as 
well as the rate of myosin dissociation. 
Contractile properties of transfected 
cardiomyocytes - We did not find any significant 
differences between the contractile properties of 
untransfected cardiomyocytes and those 
expressing untagged MHC, WT eGFP-MHC or 
mutant isoforms of eGFP-MHC (Fig. 4).  This 
might be thought to be due to the low expression 
levels of the eGFP MHC in our experiments (5-
10% of endogenous myosin). However, modelling 
has suggested that expressing α-cardiac MHC 
myosin at similar expression levels on a 
background of β-MHC has an observable effect on 
contraction kinetics (36). Therefore, if the 
mutations studied here were able to exert a strong 
effect on contraction, we would have observed it 
in these experiments. Including the eGFP tag did 
not affect contraction, with no significant 
difference between any of the parameters 
measured for cells expressing un-tagged MHC 
compared to eGFP-tagged MHC. Moreover, the 
contractile properties of myocytes expressing WT 
eGFP-MHC were not significantly different from 
untransfected cells. These results suggest that none 
of the tail mutations, expressed at up to 10% of the 
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endogenous level of myosin, directly affect 
contraction. 
Helical propensity of WT tail peptides 
containing 7, 11 or 15 heptads - The reduced 
incorporation of mutant eGFP-MHC into thick 
filaments in muscle sarcomeres for 3 out of the 6 
mutants could be due to alterations in the structure 
of the coiled-coil tail. To test this, we expressed 
and purified WT and mutant peptides containing 7, 
11, or 15 heptad repeats from the region of coiled 
coil that contains these mutations (Fig. 5, Table 
S2).  
We expected that all of the wild type (WT) 
peptides would be α-helical and form coiled coil. 
Unexpectedly, only 7H1, 11H1 and 15H1 WT 
peptides had a high α-helical content at 10˚C (Fig. 
5, Table 1), with the helical content increasing 
with length from 57% for 7H1 to 91% for 15H1. 
The five remaining 7H peptides tested (7H2 – 
7H6, Fig. 5A,C) as well as 11H2 and 15H2 (Fig. 
5F) were all less than 30% α-helical. The low 
helical content of many peptides indicates that 
they are unlikely to spend most of their time as a 
dimer, and thus as a coiled coil.   
The α-helical content of WT 11H1 and 15H1 
peptides both showed the sigmoidal dependence 
on temperature expected for the co-operative 
melting of a coiled coil (Fig. 5G & H). The Tm 
was 27°C for 11H1 and increased to 30°C for 
15H1 (Table 1).  A melting curve obtained for WT 
7H1 (at pH 7.0) was less sigmoidal in shape 
(Supplemental Fig. 2), and the estimated Tm was 
lower (17°C). The increasing Tm with increasing 
peptide length suggests that the longer peptides are 
more stable. 
These results demonstrate that sequences 
within the distal myosin tail vary widely in their 
propensity to form α-helix. Among those that we 
tested, only those containing residues 1301-1330 
had a high helical propensity (Fig. 5A). Plotting 
the sequence of this region as a heptad net (37) 
(Fig. 6) shows that there it contains a short leucine 
zipper surrounded by many oppositely charged 
residues that can interact to stabilise a helical 
conformation. This region of sequence is likely to 
have a high propensity to form a coiled coil, and 
may help longer helical peptides to do so, 
explaining the high helical nature of the 7, 11 and 
15H1 peptides. 
Impacts of mutations on helical content of tail 
peptides - The mutation that had the most severe 
effect on sarcomeric incorporation in vivo, 
N1327K, significantly decreased the α-helical 
content of 7H1, 11H1 and 15H1 peptides (Fig. 5 
B-C, E-F). The size of this decrease became less 
marked as the length of the peptide increased 
(~27% decrease for 7H1, ~16% for 11H1 and 
~11% for 15H1 (Fig. 5C & G, Table 1)). N1327K 
also reduced the Tm (Fig. 5D & H, Table 1), with 
the effect larger in the 11H1 than in the 15H1 
peptide. This mutation could be tested in each of 
the different length peptides (7H1, 11H1 and 
15H1) due to its position in the sequence. A 
second mutation (E1356K) that reduced 
sarcomeric incorporation in vivo significantly 
reduced the helical content of the 11H peptide (by 
21%, Fig. 5E,G), but had no effect on the 15H 
peptide (Fig. 5F,G), or on Tm (Fig. 5D & H, Table 
1).  
A further mutation (R1382W) that did not 
affect sarcomere incorporation in vivo 
significantly increased the helical content of the 
15H peptide (Fig. 5F,G).  The Tm was also 
increased for the mutant 15H peptide (Fig. 5H and 
Table 1). This suggests that R1382W, close to the 
skip residue (E1385), increases α-helical stability.  
The three remaining mutations tested were in 
regions of the coiled coil that did not appear to 
form highly helical structures as 7, 11 or 15H 
peptides. R1500W (in 7H3), and E1555K (in 7H4) 
both appeared to decrease helical content, and 
E1768K (in 7H5) was the only mutation in the 7H 
peptides that appeared to increase helical content. 
However, the helical contents of the wild type 
peptides are low and the differences are not 
significant. 
Overall, these peptide data show that N1327K 
has the greatest effect on the α-helical nature of 
the myosin coiled coil, reducing α-helical content 
and stability, whereas R1382W appears to increase 
the α-helical content and stability of the coiled 
coil.  
 
DISCUSSION 
Our data suggest that a reduced incorporation 
of mutant MHC into muscle sarcomeres is 
correlated with a large effect on the helical content 
of isolated peptides. Two mutations (N1327K and 
E1356K) that reduced α-helical content of 
peptides in solution also caused a reduction in 
sarcomeric incorporation of eGFP-MHC in vivo. 
In contrast, R1382W increased the α-helical 
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content of a 15 heptad peptide in solution, but had 
little effect on the incorporation of WT eGFP-
MHC into sarcomeres in vivo. Local disruptions to 
the helical nature of the rod portion of MHC may 
thus contribute to the underlying mechanism by 
which these mutations result in disease. None of 
the mutations appeared to have strong effects on 
contraction at the levels of expression (5-10% of 
endogenous myosin) obtained in our experiments, 
which is consistent with the progressive etiology 
of HCM. Finally, N1327K, the mutation that has 
the most effect on sarcomeric incorporation and α-
helical content, showed a faster rate of exchange 
into thick filaments in FRAP experiments 
compared to WT and to R1382W eGFP-MHC. 
A new trigger sequence in the myosin tail - 
Unexpectedly, as part of our research into the 
effects of mutations in vitro, we discovered that 
most 50 amino acid residue peptides do not form 
100% coiled coil in isolation. We had expected 
that the α-helical conformation of the 7 heptad 
peptides would be rapidly stabilised by forming a 
coiled coil, as all of them show a hydrophobic 
seam in their sequence (Fig 6A-F). However, with 
the exception of 7H1, all the 7H peptides had a 
low α-helical content, suggesting that they remain 
largely unfolded and/or form an alternative fold. 
Moreover, increasing the lengths of such peptides 
to 11 or even 15 heptads did not necessarily 
increase the α-helical content. Peptides had to 
contain the sequence within residues 1301-1329 to 
contain significant amounts of α-helix/coiled coil, 
suggesting that this region is important for coiled 
coil formation, possibly acting as a ‘trigger 
sequence’ in the tail.  Trigger sequences have a 
high propensity to form α-helix and then assemble 
to form coiled coil with the trigger sequence 
region on a second peptide (38). This promotes 
folding and coiled-coil formation along the whole 
molecule. Any sequence that favours interchain 
and intrachain interactions may act as a trigger 
(39).  
Plotting the 7H1 as a heptad net (Fig 6A) 
shows that there are many potential attractive 
intrachain interactions (including Q-E interactions) 
between successive turns of helix within 1309-
1322 (boxed region, Fig. 6A), which will promote 
formation of α-helix. These interactions surround a 
short leucine zipper (leucines in the a, d and 
subsequent a positions). Together, these may 
account for the stability and helix propensity of 
this region of the coiled coil. Fewer interactions, 
and a lack of leucine residues in the hydrophobic 
seam may explain why downstream sequences 
(7H2-6, 11H2 and 15H2) have a lower propensity 
to form coiled coil in isolation. However, when the 
sequences of 7H2 and 7H3 (Fig 6B,C), are 
incorporated into 11H1 and 15H1, they do become 
helical presumably due to the influence of the 
upstream sequence from 7H1. 
Molecular basis of effects of tail mutations - 
All of the mutations we studied affected the helical 
content and coiled coil formation of 7H peptides. 
Three mutations, N1327K, E1356K and E1555K, 
which decreased helical content in isolated 
peptides, also decreased incorporation of full-
length myosin into the thick filament in vivo. This 
suggests that reducing the helical content could 
contribute to a decreased ability of these mutant 
isoforms to incorporate normally into thick 
filaments, and an increased chance that the mutant 
myosin forms aggregates outside the muscle 
sarcomeres. This may explain why all three of 
these mutations result in a more severe form of 
HCM (18,20) (Table S1). The non-incorporated 
aggregated myosin may be proteotoxic, supporting 
the recently suggested idea that protein misfolding 
is a major contributor to hypertrophic 
cardiomyopathy (40).  
The reduced helical content that we observed 
for each of these three mutations may result from 
the introduction of an intra-chain repulsion. 
N1327K (b position in the heptad) introduces an 
intra-chain repulsion between this residue and 
K1323 in the preceding turn of helix (Fig. 6A). 
E1356K replaces an intra-chain attraction between 
this residue and R1359 into a repulsive one (Fig. 
6B), which is likely to affect coiled coil stability. 
In contrast, E1555K (e position) replaces a 
potentially repulsive interaction between this 
residue and E1552 with an attractive one (Fig. 
6D). Finally, our observation that the effects of 
mutations on α-helical content decrease as the 
lengths of the peptide increase helps to explain 
why an earlier study, using the full-length 
filament-forming region of the tail (LMM), found 
no effect of E1356K on α-helical content (22).   
In addition to reducing helical content, each of 
these mutants, in residues on the outside of the 
coiled coil, has the potential to affect packing of 
the myosin heavy chain into the thick filament. 
Both E1356 (in a ‘c’ position) and E1555K (‘e’ 
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position) are in patches of glutamates (Fig. 6B & 
D). A mutation to lysine decreases the net charge 
of these patches by two. This has the potential to 
affect integration of the molecule into the thick 
filament, which depends on the pattern of 
alternating negative and positive charge along the 
coiled coil (41).  In addition, E1555K is in a 
region of LMM implicated in binding to other 
thick filament proteins such as Myosin Binding 
Protein C (MyBPC; thought to lie between 
residues 1554 and 1581), Myomesin and M-
protein (thought to lie between residues 1506 and 
1674) (42-44). While mutation of E1555 to Q in 
earlier experiments showed it did not affect 
MyBPC binding (42), it has not been determined if 
E1555K affects binding of MyBPC, myomesin 
and/or M-line protein.  
Two further mutations, R1382W and E1768K 
had little effect on sarcomeric incorporation but 
are associated with increased helical content in the 
15H and 7H peptides respectively. R1382W (a 
position, Fig. 6F) is close to one of the skip 
residues (E1385), thought to correlate to the bends 
in the myosin tail in the extended molecule (3). 
This mutation may increase α-helical content by 
stabilising the sequence close to the skip residue, 
as tryptophan is more hydrophobic than arginine, 
and may become more buried (Fig 6F). In 
addition, this mutation would abolish any inter-
chain attractive forces between R1382 (a position) 
and both D1378 and E1385 in adjacent d 
positions. E1768 (g) is partnered with Q1773 (e) 
on the other helix, which cannot form an ionic 
interaction (Fig 6E). However, within the chain it 
can make an ionic interaction with K1771. Its 
mutation to K would result in a repulsive 
interaction with K1771 (Fig. 6E), but introduce a 
novel ionic interchain bonding with E1772 (d) 
emerging from the coiled-coil seam. This might be 
expected to disfavour helix stability, in contrast to 
our observation that this mutation increases the 
helical content of a weakly helical 7H peptide. 
Thus the mechanism of disease by these 
apparently benign mutations remains obscure. 
R1500W causes DCM rather than HCM, albeit 
with a late onset (age 55+ (17)). We found that 
this mutation abolished the already low helical 
content of a 7H peptide.  R1500W could decrease 
α-helical content through the loss of a potential 
attractive force between R1500 (f position) and 
E1496 (b) (see Fig. 6C).  This mutation also 
replaces a polar residue with a bulky hydrophobic 
one, in an ‘f’ position in the heptad repeat in 
which residues are usually polar. In the tail of wild 
type β-MHC, tryptophan is not found in any of the 
‘f’ positions in the heptad repeats. Introducing a 
bulky hydrophobic residue out in solution as a 
result of this mutation might be expected to affect 
molecular structure. Previous work has shown that 
this mutation decreases the Tm of LMM (by 
2.3°C) and decreases assembly into filaments in 
vitro (as observed by light scattering) (23). 
However, we found that this mutation had little 
effect on sarcomeric incorporation in vivo. 
Exchange of myosin in thick filaments is 
quicker than turnover - The rate of exchange of 
eGFP MHC into myofibrils that we observed in 
FRAP experiments is much faster than the slow 
rate of turnover of MHC protein in the beating 
heart. The half-life for myosin turnover is long, 
recently measured as ~15 days in hearts from rats 
(45). Similarly, exchange rates for several Z-disc 
proteins measured using FRAP were also found to 
be much faster than the turnover rates for these 
proteins (46). A rapid exchange rate would enable 
newly synthesised MHC to be rapidly and 
efficiently exchanged into the thick filament 
within the muscle sarcomere, without 
disassembling the existing myofibrils, thus 
maintaining force output.  
Our experiments with N1327K showed that this 
mutation increased exchange rates. We think it is 
likely that the other mutations in the rod domain of 
myosin that result in HCM could also affect 
exchange rates. This change in exchange rates 
could result from the reduction in local helical 
stability. This suggests the possibility that in 
patients harbouring mutations in the myosin rod, 
disease results from a defective exchange/turnover 
process, which has the potential to decrease force 
output in the heart. Interestingly, this has some 
analogies with skeletal muscle diseases such as 
Laing distal myopathy, a disease of skeletal 
muscle that also involves mutations in the rod 
portion of myosin, and results in muscle weakness 
(47). Defective myosin is known to accumulate 
outside the muscle sarcomeres in this disease. It is 
also possible that the mutation also affects the 6S-
10S equilibrium, although it is unknown whether 
cardiac muscle myosin adopts a compact 
conformation in vivo. A partially compact 
conformer has been observed in vitro (48).    
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We have reported here, for the first time, that 
eGFP MHC can incorporate normally into muscle 
sarcomeres, without affecting contraction, and that 
eGFP-MHC can exchange into muscle sarcomeres, 
(half time of about 30 minutes). This is the first 
time that the behaviour of a full-length eGFP-
MHC has been studied in adult cardiomyocytes 
and that it has been directly demonstrated the 
myosin can exchange into thick filaments. Since 
the thick filament contains 294 myosin molecules 
(49), the measured FRAP half time suggests a 
molecule of myosin exchanges into a thick 
filament every 10 seconds on average, making the 
thick filament a more dynamic assembly than is 
generally perceived. 
Our approach of expressing eGFP-tagged full-
length MHC in adult rat cardiomyocytes using an 
adenoviral delivery system has allowed us to 
measure the dynamic behaviour of myosin in live 
cells as well as to directly investigate the impact of 
HCM mutations in vivo. By contrast, previous 
studies have used a GFP-tagged myosin tail 
(50,51), or untagged MHC (52), or expressed the 
eGFP-MHC in neonatal rather than adult 
cardiomyocytes (53). This methodology should 
have wide applicability to gaining understanding 
of the mechanism of cardiomyopathies deriving 
from any myofibrillar protein.   
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FIGURE LEGENDS 
 
FIGURE 1. Expression and incorporation of eGFP-MHC in adult cardiomyocytes. A. The fluorescence 
pattern for eGFP-MHC 24 hours after adding adenovirus is similar to that observed for endogenous 
MHC, using an antibody that recognises the motor domain of myosin (A4.1025). Co-labelling with an 
anti-M-line titin antibody (Ti51) confirms that the wider gap in fluorescence observed for eGFP-MHC is 
at the M-line. Black arrows indicate the positions of Z-discs. B. Fluorescence images of part of a 
cardiomyocyte, corresponding to one myofibril in width, expressing eGFP-MHC and co-stained for MHC 
using an antibody. The corresponding line profiles for the fluorescence images are shown below, 
demonstrating how fluorescence intensity varies along the myofibril for MHC and for eGFP-MHC. 
Arrows indicate the positions of Z-discs.  C. Images of a Coomassie stained SDS gel, and corresponding 
immunoblots probed using antibodies to eGFP or to myosin heavy chain (A4.1025) to identify the bands 
for eGFP-tagged and endogenous MHC. 
 
FIGURE 2.  Analysis of eGFP-MHC incorporation in adult cardiomyocytes. A. Representative images 
showing normal incorporation contrasted with poor incorporation with filamentous aggregates. Black 
arrows show the positions of Z-disks. White arrows show filamentous aggregates. The images shown are 
for the N1327K mutant. B. Quantification of eGFP incorporation for WT and each of the mutants.  The 
results shown are the mean values (+/- SEM) for 3-6 experiments.  The % of cells with aggregates (shown 
in white) was significantly higher in N1327K expressing cells compared to WT cells (p<0.05). The % of 
cells without aggregates is shown in grey. 
 
FIGURE 3. FRAP analysis of eGFP-MHC dynamics in living cardiomyocytes. A: sample images from a 
FRAP experiment showing a region from a single cardiomyocyte expressing wild type eGFP-MHC, in 
which the bleached square is in the centre. The pre-bleach image, followed by the immediate post-bleach 
image, and subsequent images at 45 and 125 minutes are shown. Arrows indicate location of fluorescence 
recovery near Z-discs. B: Time course of FRAP data for WT (n=14), N1327K (n=18) and R1382W 
(n=18), showing the means +/- S.E.M. at each time point, and the exponential fits to the data.  
 
FIGURE 4. Contraction data for rat ventricular myocytes cultured for 24 hours that were untransfected, 
expressing WT-MHC, WT GFP-MHC or mutant WT GFP-MHC. Myocytes were stimulated to contract 
at a frequency of 1Hz. Data are shown as mean ± S.E.M. Values for n are: 9 (Control Untransfected), 14 
(WT MHC), 14 (WT GFP-MHC), 12 (N1327K) 20 (E1356K), 11 (R1382W), 14 (R1500W), 11 
(E1555K) and 13 (R1768K). A. Time from stimulation to peak shortening. B. Time of half relaxation 
from peak shortening to resting cell length. C. Contractility expressed as the amplitude of cell shortening 
as a % of resting cell length. No significant differences were found between any of the measurements.  
 
FIGURE 5. Properties of wild type and mutant peptides. A. Diagram of the positions of the tail peptides 
and mutants investigated in the tail. The black line represents a scale bar of 100 amino acids alongside the 
coiled-coil tail of the myosin. The positions of the 4 skip residues are shown by grey dotted lines. The 
shaded rectangles show the positions, with respect to their positions in the tail of myosin, of each of the 
peptides investigated, in which overlapping sequence in different peptides is shown in the same 
colour/pattern. E.g. heptad H1 is shown in black, and the start of heptad 7H2 is shown as black, as it 
contains the C-terminal sequence of heptad 7H1. The filled stars denote the relative α-helical content of 
each peptide (see key). The vertical rectangle shown using a dashed line shows the region of the sequence 
required for high α-helical content. B. CD spectra for the 7H1 WT and mutant (N1327K) peptides. (pH 
8.0, 150mM NaCl, 10mM phosphate buffer) C. Summary plot of the values for θ222 (MRW) (which 
reports on α-helical content) measured for each of the WT 7H peptides (shown as black bars) and the 
corresponding mutant (shown as white bars). Conditions used were pH 8.0, 150mM NaCl, 10mM 
phosphate buffer. The mean together with the standard error is shown.  The decrease in helical content for 
N1327K is significant (p<0.05).  D. Normalised thermal melt curves for 11H peptides (pH 7.0, 50mM 
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NaCl, 10mM phosphate buffer). E. CD spectra for the WT and mutant 11H1 peptides (pH 7.4, 50mM 
NaCl, 10mM phosphate buffer). F.  CD spectra for the WT and mutant 15H1 peptides (pH7.4, 50mM 
NaCl, 10mM phosphate buffer). G. Summary plot of the θ222 (MRW) values for the WT 11H1 (black 
bars), and 15H1 (black bars), mutant 11H1 and 15H1 peptides (white bars) as shown in E and F, together 
with the value for the WT 11H2 and 15H2 peptides (grey bars). Significant changes in helical content 
between WT and mutant peptides are indicated by asterisks, where * is p<0.05, ** is p<0.01 and *** is 
p<0.001.  H Normalised thermal melt curves for 15H peptides (pH 7.0, 50mM NaCl, 10mM phosphate 
buffer).  
 
FIGURE 6. Heptad net plots of each of the WT 7H peptides tested. A to F shows peptides 7H1 to 7H6.  
In each plot, the preferred intra-chain ionic interactions (see (37,54)) are shown as solid lines. In addition 
alternative/other interactions are shown as dotted lines. Every seventh residue is repeated on the right of 
the plot (in brackets) so that all interactions can be shown. The gray dashed lines indicate the path of the 
polypeptide backbone; the green dotted line defines the orientation of the α-helix axis. The light gray 
circles indicate ‘‘a’’ positions and the squares indicate ‘‘d’’ positions that form the hydrophobic seam. In 
A: the boxed region (dashed lines) within this 7H1 peptide that favours coiled coil formation is shown. 
The black hexagons (dashed lines) indicate the positions of the mutant residues within each sequence.  
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Table 1. Estimates of the % helical contents and melting temperatures (Tm) for each 11H and 
15H peptide and associated mutant. Melting curves were only performed once. Tm was 
estimated as described in the methods.  
 
 
Peptide Mutation/WT α-helical 
content 
(pH 7.4) 
(%) ± 
SEM 
Tm 
pH 7.0 
(10°C) 
ΔTm 
compared 
to WT 
11H1 WT 79 ± 1 26.9 - 
11H1 N1327K 66 ± 2 22.3 -4.6 
11H1 E1356K 62 ± 2 26.2 -0.7 
15H1 WT 91 ± 1 29.7 - 
15H1 N1327K 81 ± 3 27.8 -1.9 
15H1 E1356K 90 ± 2 30.0 +0.3 
15H1 R1382W 98 ± 2 33.8 +4.1 
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Figure 1 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
 
 
